Martin Shkreli has a plan to increase the price of a Chagas drug called benznidazole.
Martin Shkreli plans to seek approval from the U.S. Food and Drug Administration (FDA) for the Chagas drug that has been around for years and has been used in tropical countries. He would submit the drug to get vouchers that can be sold to other companies for millions of dollars, reports The New York Times.
Martin Shkreli intentions have caused worry in the Chagas community. Benznidazole isn’t approved in the U.S, but the Centers for Disease Control and Prevention gives it to patients for free when labeled as being used for experiments. The drug currently only costs $50 to $100 for a two-month treatment in Latin America, NYT notes.
This isn’t Martin Shkreli’s first time appearing unpopular in the public eye. He increased the price of an AIDS drug by 5000% in September and lowered the price after backlash, but not back to previous levels. He
was also recently named the new CEO of KaloBios (KBIO) after leading an investor group to obtain a 70% stake in the company.
More From InvestorPlace:
